Clinical Trial Update: A Phase 3 Study of NTLA-2001 in ATTRv-PN [Phase 3]

View source ↗

Summary

NTLA-2001, Intellia's in vivo gene-editing therapy, is in Phase 3 for hereditary transthyretin-mediated amyloidosis with polyneuropathy and the trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• NTLA-2001

Snippet

Sponsor: Intellia Therapeutics | Conditions: Neuromuscular Disease, Neuromuscular Diseases (NMD) | Phase 3 | Status: RECRUITING